Meta-iodobenzylguanidine (MIBG), has a combination of the structural features of bretyllium and guanethedine. MIBG has been found to be a potential adrenomedullary agent as well as a radiopharmaceutical for other diagnostic and therapeutic applications. For example, MIBG, radiolabeled with iodine-131 and iodine-123, has been used in the diagnosis of heart abnormalities and neuroendocrine tumors. [131I]MIBG also has been used for the treatment of neuroendocrine tumors. With the currently used method (isotopic exchange), radioiodinated MIBG cannot be obtained at a no-carrier-added (n.c.a.) level. This may diminish its clinical utility for some applications. there are some shortcomings in [131I]MIBG therapy, especially for neuroblastoma, attributed to the physical characteristics of iodine-131. The physical characteristics of astatine-211 could be more suitable for the treatment of neuroblastoma since astatine-211 emits alpha particles of high linear energy transfer. It may be advantageous to have MIBG analogs labeled with positron- emitting nuclides for positron emission tomographic imaging. The objectives of this proposal are to develop synthetic methods for the preparation of n.c.a. [131I]MIBG,3- [211At]astatobenzylguanidine([211At]MABG)3- [18F]fluorobenzylguanidine([18F]MFBG) and 4-[18F]fluoro-3- iodobenzylguanidine([18F]FIBG) and to evaluate their potential as diagnostic and therapeutic radiopharmaceuticals. First, the in vitro binding characteristics of each of the new agents will be studied using neuroblastoma cell lines. Biodistribution of these agents will be determined initially in normal mice and subsequently in athymic mouse human neuroblastoma xenograft models. These studies should give information on the potential utility of these agents as MIBG analogs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29CA060066-02
Application #
2100673
Study Section
Diagnostic Radiology Study Section (RNM)
Project Start
1993-04-01
Project End
1998-03-31
Budget Start
1994-04-01
Budget End
1995-03-31
Support Year
2
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Duke University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
Vaidyanathan, G; Zalutsky, M R; DeGrado, T R (1998) Iodopyridine-for-iodobenzene substitution for use with low molecular weight radiopharmaceuticals: application to m-iodobenzylguanidine. Bioconjug Chem 9:758-64
DeGrado, T R; Zalutsky, M R; Coleman, R E et al. (1998) Effects of specific activity on meta-[(131)I]iodobenzylguanidine kinetics in isolated rat heart. Nucl Med Biol 25:59-64
Vaidyanathan, G; Zhao, X G; Strickland, D K et al. (1997) No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog. J Nucl Med 38:330-4
Vaidyanathan, G; Affleck, D J; Zalutsky, M R (1996) No-carrier-added (4-fluoro-3-[131I]iodobenzyl)guanidine and (3-[211At]astato-4-fluorobenzyl)guanidine. Bioconjug Chem 7:102-7
Vaidyanathan, G; Friedman, H S; Keir, S T et al. (1996) Evaluation of meta-[211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model. Nucl Med Biol 23:851-6
Vaidyanathan, G; Friedman, H S; Keir, S T et al. (1996) Localisation of [131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effect of specific activity. Br J Cancer 73:1171-7
Vaidyanathan, G; Zalutsky, M R (1996) Targeted therapy using alpha emitters. Phys Med Biol 41:1915-31
Vaidyanathan, G; Affleck, D J; Zalutsky, M R (1995) Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG. J Nucl Med 36:644-50
Vaidyanathan, G; Zalutsky, M R (1995) No-carrier-added meta-[123I]iodobenzylguanidine: synthesis and preliminary evaluation. Nucl Med Biol 22:61-4
Degrado, T R; Zalutsky, M R; Vaidyanathan, G (1995) Uptake mechanisms of meta-[123I]iodobenzylguanidine in isolated rat heart. Nucl Med Biol 22:1-12

Showing the most recent 10 out of 14 publications